Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Apple Turns 50: From Garage Startup to AI Crossroads 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
SEATTLE, Sept. 07, 2017 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it will webcast the company’s presentation at the 2017 Morgan Stanley Global Healthcare Conference in New York City, on Tuesday, September 12, 2017.
The webcast is scheduled to begin at 3:30pm ET and will feature a company overview by Brad Gray, president and chief executive officer of NanoString. Interested parties can access the live webcast from the investor section of the company’s website at www.nanostring.com. The webcast replay will be available one hour after the conclusion of the live presentation and archived for 90 days.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,650 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
NanoString, NanoString Technologies, the NanoString logo, 3D Biology, nCounter and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
Contact: Doug Farrell Vice President, Investor Relations & Corporate Communications [email protected] Phone: 206-602-1768
